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Abstract 
Aims: Admission hyperglycemia is associated with increased mortality and major adverse cardiac events (MACE) in 
patients with or without diabetes mellitus after acute myocardial infarction (AMI). However, effects of glycemic vari‑
ability (GV) on outcomes of non‑diabetes patients with AMI still remains unclear. The aim of this study is to compare 
the prognostic value of in‑hospital GV with admission blood glucose (ABG) for 3‑month MACE in non‑diabetes 
patients with ST elevation myocardial infarction (STEMI) who underwent percutaneous coronary intervention (PCI).
Methods: We analyzed 256 non‑diabetes patients with STEMI in study. The GV accessed by mean amplitude of 
glycemic excursions (MAGE) was calculated from blood glucose profiles of continuous glucose monitoring system 
(CGMS) during hospitalization. ABG was measured on admission. Main endpoints were 3‑month MACE; secondary 
endpoints were GRACE scores and enzymatic infarct size. Predictive effects of MAGE and ABG on the MACE in patients 
were analyzed.
Results: In all participants, MAGE level was associated with ABG level (r = 0.242, p < 0.001). Both elevated MAGE 
levels (p = 0.001) and elevated ABG (p = 0.046) were associated with incidences of short‑term MACE. Patients with a 
higher MAGE level had a significantly higher cardiac mortality (5.8 vs. 0.6%, p = 0.017) and incidence of acute heart 
failure (12.8 vs. 2.4%, p = 0.001) during 3 months follow‑up. In multivariable analysis, high MAGE level (HR 2.165, 
p = 0.023) was significantly associated with incidence of short‑term MACE, but ABG (HR 1.632, p = 0.184) was not. 
The area under the receiver‑operating characteristic curve for MAGE (0.690, p < 0.001) was superior to that for ABG 
(0.581, p = 0.076).
Conclusions: To compare with ABG, in‑hospital GV may be a more important predictor of short‑term MACE and mor‑
tality in non‑diabetes patients with STEMI treated with PCI.
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Background
Acute hyperglycemia on admission is common in non-
diabetes patients with acute myocardial infarction (AMI), 
and is a risk factor for increased mortality and in-hospital 
adverse outcomes [1, 2]. It has shown that high admission 
blood glucose (ABG) levels are associated with increased 
mortality after AMI [3, 4]. However, recent studies have 
shown that glycemic variability (GV) may be of prognos-
tic value with regard to future cardiovascular events [5, 
6]. Some studies showed that glucose fluctuations could 
play a deleterious role through the activation of oxida-
tive stress, one of the key pathophysiological mechanisms 
for the development of cardiovascular complications [7, 
8]. However, whether GV has the important prognostic 
significance of short-term major adverse cardiac events 
(MACE) in non-diabetes patients is unknown. In this 
study, we investigated the independent prognostic value 
of the in-hospital GV and ABG levels in patients without 
known diabetes mellitus who underwent percutaneous 




This was a single-center, prospective follow-up study. 265 
non-diabetes patients with STEMI who underwent PCI 
had baseline clinical and laboratory studies, including 
the Global Registry of Acute Coronary Events (GRACE) 
risk scores [9], the mean amplitude of glycemic excur-
sions (MAGE) and ABG levels (All patients’ ABG level 
is less than 16.7  mmol/L). STEMI was defined as com-
plaints of chest pain with ECG signs compatible with 
AMI (ST-segment elevation  >2  mm in precordial leads 
and  >1  mm in limb leads). Thrombolysis in Myocardial 
Infarction (TIMI) flow was scored according to the TIMI 
flow grading system before and after PCI. Myocardial 
infarct size was measured by peak creatinine kinase (CK) 
level in the first 24  h after admission. Diabetes mellitus 
was diagnosed according to the American Diabetes Asso-
ciation criteria or the use of insulin or glucose-lowering 
medication. Hypertension was defined as systolic blood 
pressure  ≥140  mmHg and/or diastolic blood pres-
sure ≥90 mmHg or treatment with oral antihypertension 
drugs. Hyperlipidemia was diagnosed according to the 
modified National Cholesterol Education Program-Adult 
Treatment Panel III. The estimated glomerular filtration 
rate (eGFR) value was calculated by modification of diet 
in renal disease equation [10].
To enable completed follow-up and repeated visits 
to our outpatient clinic, only patients under the age of 
80 and living within the hospital’s catchment area were 
eligible. The exclusion criteria were severe non-cardiac 
disease with expected survival of less than 3  months 
and unwillingness to participate. A patient could 
only be included once. Thus, 256 patients with com-
plete data were included in the final analysis. Patients 
were categorized according to MAGE and ABG value, 
respectively (MAGE group1: the highest tertile, MAGE 
>3.26  mmol/L; MAGE group2: MAGE  ≤3.26  mmol/L; 
ABG group1: the highest tertile, ABG >7.8 mmol/L; ABG 
group2: ABG  ≤7.8  mmol/L). Blood samples were col-
lected on admission in Emergency department and after 
overnight fasting and stored at −70 °C prior to analysis. 
Blood glucose, creatinine, total cholesterol, and triglycer-
ide levels were measured by automatic biochemical ana-
lyzer (Hitachi 747; Hitachi, Tokyo, Japan).
Continuous glucose monitoring
All patients were equipped with continuous glucose 
monitoring system (CGMS, Medtronic MiniMed, USA), 
and were monitored for 72 consecutive hours after PCI. 
A CGMS sensor was inserted into the subcutaneous 
abdominal fat tissue, calibrated according to the standard 
Medtronic MiniMed operating guidelines. During CGMS 
monitoring, patients checked their blood glucose level 
with a self-monitoring of blood glucose (SMBG) device 
(Medisafe Mini, Terumo, Japan) at least 4 times per day. 
Then, they entered the SMBG data and time of each meal 
into the CGMS. After monitoring for 72 h, the recorded 
data were downloaded into a personal computer for anal-
ysis of the glucose profile and glycemic excursion param-
eters with MiniMed Solutions software. The MAGE was 
calculated from the intermediate 24  h of recordings to 
avoid bias due to insertion and removal of the CGMS 
or insufficient stability of the monitoring system. Since 
measurable range of glucose by CGMS was mechanically 
limited from 2.2 to 22.2  mmol/L, the case showing the 
data out of this range was excluded from the study. The 
MAGE was calculated by measuring the arithmetic mean 
of the differences between consecutive peaks and nadirs, 
provided that the differences are greater than one stand-
ard deviation of the mean glucose value [11]. Patients 
would avoid glucose infusion during CGMS monitoring 
period. Otherwise, the patient would be excluded from 
the study.
Coronary intervention
All patients were performed with subsequent PCI when 
indicated as part of the routine treatment for all STEMI 
patients in Beijing An Zhen Hospital. Coronary interven-
tion was performed using standard techniques, includ-
ing percutaneous transluminal coronary angioplasty, 
thrombus aspiration, intracoronary stenting, and/or 
mechanical rotational atherectomy. The PCI strategy 
was at the operator’s discretion. All patients were pre-
treated with aspirin, heparin, and clopidogrel before 
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PCI. After intracoronary stent implantation, all patients 
received aspirin and clopidogrel for at least 6  months. 
Other adjunctive pharmacotherapy was administered at 
the discretion of the operator. Repeat cardiac catheteriza-
tion was performed for recurrent symptoms or objective 
evidence of ischemia during provocative testing. Routine 
angiographic follow-up was not undertaken.
Follow‑up
All patients meeting criteria for this analysis were invited 
to participate in the study. After informed consent was 
obtained from the patient or a family member, clinical 
follow-up was performed by telephone interview and 
review of hospital records. Patients were followed up pro-
spectively for 3  months. During follow-up period, inci-
dences of MACE were registered, including new-onset 
myocardial infarction, acute heart failure, repeat target 
vessel revascularization (TVR) after initial revasculariza-
tion and cardiac death. All MACE data were adjudicated 
by an experienced cardiovascular physician blinded to 
clinical details and outcomes.
Statistical analysis
All statistical analyses were performed by using SPSS for 
Windows 20.0 (SPSS Inc, Chicago, IL, USA). Data are pre-
sented as frequencies and percentages for categorical var-
iables, median for abnormal distributed parameters and 
mean ±  SD for continuous  distributed variables, unless 
otherwise indicated. Differences between two groups 
were assessed by using the Chi square,  Mann-Whitney 
rank analysis and unpaired t-tests. Correlation between 
continuous variables was determined by Pearson corre-
lation coefficients. The primary end point was 3-month 
MACE. Secondary end points were GRACE scores and 
enzymatic infarct size. MAGE levels were included as 
continuous and as categorized (≤3.26 or >3.26 mmol/L) 
variables. ABG levels were also included as continuous 
and categorized (≤7.8 or  >7.8  mmol/L) variables. The 
predictive values of MAGE and ABG for the presence of 
MACE were calculated by constructing receiver-operat-
ing characteristic (ROC) curves. To ascertain the inde-
pendent contribution to MACE, multivariate regression 
analysis was made (Cox regression using backward step-




During the study period, 265 patients were enrolled. 256 
patients (96.6%) with complete data were included in the 
final analysis (9 patients were removed from study, 5 for 
failure of CGMS monitoring and 4 for incomplete fol-
low-up data). Mean age was 61.7 ± 6.4 years, 60.5% were 
male. Baseline characteristics of patient groups based on 
levels of MAGE and ABG are shown in Tables 1 and 2. 
There was a strong correlation between MAGE and ABG 
(Pearson r = 0.242, p < 0.001). Higher MAGE or higher 
ABG was older, and more often had lower values of left 
ventricular ejection fraction (LVEF) and eGFR. High 
MAGE levels were associated with more frequent pres-
ence of multivessel disease and more stents planted.
Outcomes of patients
At the end of 3-month follow-up, 6 patients had died 
(2.3%) for cardiac causes, 8 patients had new-onset myo-
cardial infarction (3.1%), 15 patients had acute heart fail-
ure (5.9%) and 21 patients had TVR (8.2%). Incidence 
Table 1 Baseline characteristics in  non-diabetic patients 
with STEMI based on MAGE levels
Data are mean ± SD and number (%)
STEMI ST elevated myocardial infarction, MAGE the mean amplitude of glycemic 
excursions, BMI body mass index, MI myocardial infarction, PCI percutaneous 
coronary intervention, CABG coronary artery bypass graft, LVEF left ventricular 
ejection fraction, eGFR estimated glomerular filtration rate, TC total cholesterol, 
TG triglyceride, ABG admission blood glucose, HbA1c glycated hemoglobin, LAD 





 Age (years) 61 (39–77) 64 (36–79) <0.001
 Males 99 (58.2) 56 (65.1) 0.344
 BMI (kg/m2) 26.6 (20.3–33.1) 26.7 (22.5–41.9) 0.727
Medical history
 Prior MI 16 (9.4) 14 (16.3) 0.148
 Prior PCI 26 (15.3) 14 (16.3) 0.857
 Prior CABG 10 (5.9) 7 (8.1) 0.596
Risk factors
 Hypertension 112 (65.9) 61 (70.9) 0.480
 Hyperlipidemia 87 (51.2) 54 (62.8) 0.085
 Current smoking 82 (48.2) 47 (54.7) 0.356
 LVEF (%) 55.47 ± 9.94 50.27 ± 9.89 <0.001
 eGFR (mL/min/1.73 m2) 71.67 ± 29.05 62.55 ± 17.76 0.008
 TC (mmol/L) 4.60 ± 0.95 4.67 ± 1.02 0.588
 TG (mmol/L) 1.82 ± 1.39 1.90 ± 0.73 0.591
 ABG (mmol/L) 7.01 ± 1.68 7.91 ± 2.20 <0.001
 MAGE (mmol/L) 2.17 ± 0.73 4.28 ± 1.06 <0.001
 HbA1c (%) 4.71 ± 0.90 5.70 ± 1.50 <0.001
Angiographic data
 Culprit vessel, LAD 68 (40.0) 38 (44.2) 0.591
 Multi‑vessel CAD 78 (45.9) 53 (61.6) 0.024
 TIMI grade 3 before PCI 46 (27.1) 15 (17.4) 0.120
 TIMI grade 3 after PCI 163 (95.9) 78 (90.7) 0.156
 Stents 1.51 ± 0.87 1.79 ± 1.09 0.027
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of total short-term MACE was significantly higher 
with increasing MAGE levels and ABG levels. GRACE 
scores and infarct size measured by peak CK were also 
strongly associated with higher MAGE and ABG lev-
els. To compare with patients of lower MAGE, higher 
MAGE patients had significantly higher cardiac mortal-
ity (5.8 vs. 0.6%, p = 0.017) and incidence of acute heart 
failure (12.8 vs. 2.4%, p = 0.001). Differences of rates of 
cardiac death, repeat infarction, acute heart failure and 
TVR were not statistically significant between two ABG 
groups (Table 3 and Fig. 1).
Multivariate analysis
Cox regression analysis was used to investigate the asso-
ciations of MAGE and ABG with incidences of MACE 
with adjusting for age, sex, and all possible predictors 
of MACE (prior MI, hypertension, hyperlipidemia, cur-
rent smoking, eGFR, LVEF, body mass index, multivessel 
coronary artery disease, anterior infarction, TIMI flow 
before PCI and TIMI flow after PCI). Results of analy-
sis showed that MAGE (HR 2.165, 95% CI 1.114–4.219, 
p  =  0.023), but not ABG, was significantly associated 
with short-term MACE. Significant predictors are pre-
sented in Table 4.
ROC curve for MAGE and ABG in predicting short‑term 
MACE
The area under the ROC curve for MAGE (0.690, 95% 
CI 0.605–0.775, p < 0.001) was superior to that for ABG 
(0.581, 95% CI 0.492–0.670, p = 0.076) (Fig. 2). MAGE, 
but not ABG, displayed significant value in predicting 
short-term MACE in patients.
Discussion
Our study shows that an elevated MAGE level during 
hospital is associated with a significantly higher risk of 
short-term MACE and cardiovascular mortality after 
Table 2 Baseline characteristics in  non-diabetic patients 
with STEMI based on ABG levels
Data are mean ± SD and number (%)
STEMI ST elevated myocardial infarction, ABG admission blood glucose, BMI body 
mass index, MI myocardial infarction, PCI percutaneous coronary intervention, 
CABG coronary artery bypass graft, LVEF left ventricular ejection fraction, eGFR 
estimated glomerular filtration rate, TC total cholesterol, TG triglyceride, MAGE 
the mean amplitude of glycemic excursions, HbA1c glycated hemoglobin, LAD 





 Age (years) 60 (36–79) 64 (44–72) 0.011
 Males 105 (61.8) 50 (58.1) 0.590
 BMI (kg/m2) 26.6 (23.5–41.9) 26.6 (20.3–32.7) 0.233
Medical history
 Prior MI 18 (10.6) 12 (14.0) 0.420
 Prior PCI 27 (15.9) 13 (15.1) 1.000
 Prior CABG 11 (6.5) 6 (7.0) 1.000
Risk factors
 Hypertension 114 (67.1) 59 (68.6) 0.888
 Hyperlipidemia 92 (54.1) 49 (57.0) 0.692
 Current smoking 88 (51.8) 41 (47.7) 0.597
 LVEF (%) 55.81 ± 10.34 51.57 ± 9.80 0.017
 eGFR (mL/min/1.73 m2) 73.54 ± 28.54 58.85 ± 16.86 <0.001
 TC (mmol/L) 4.58 ± 0.96 4.71 ± 0.95 0.287
 TG (mmol/L) 1.81 ± 1.39 1.93 ± 0.75 0.376
 ABG (mmol/L) 6.17 ± 1.07 9.56 ± 1.27 <0.001
 MAGE (mmol/L) 2.62 ± 1.15 3.40 ± 1.45 <0.001
 HbA1c (%) 4.76 ± 1.28 5.81 ± 1.42 <0.001
Angiographic data
 Culprit vessel, LAD 65 (38.2) 41 (47.7) 0.179
 Multi‑vessel CAD 82 (48.2) 49 (57.0) 0.233
 TIMI grade 3 before PCI 43 (25.3) 18 (20.9) 0.535
 TIMI grade 3 after PCI 162 (95.3) 79 (91.9) 0.273
 Stents 1.54 ± 0.911 1.72 ± 1.04 0.170
Table 3 Clinical outcomes of non-diabetic patients with STEMI based on MAGE and ABG
Data are mean ± SD and number (%)
STEMI ST elevated myocardial infarction, MAGE the mean amplitude of glycemic excursions, ABG admission blood glucose, CK creatine kinase, MACE major adverse 
cardiac events, MI myocardial infarction, HF heart failure, TVR repeat target vessel revascularization
MAGE (mmol/L) ABG (mmol/L)
≤3.26 >3.26 p ≤7.80 >7.80 p
n 170 86 170 86
Peak CK (U/L) 905 (300–4077) 1290 (471–4658) 0.020 897 (300–4428) 1372 (398–4658) 0.039
GRACE score 140 ± 33 152 ± 34 0.005 141 ± 34 150 ± 33 0.036
MACE 20 (13.5) 30 (31.4) 0.001 26 (15.9) 24 (26.7) 0.046
 Cardiac death 1 (0.6) 5 (5.8) 0.017 2 (1.2) 4 (4.7) 0.100
 New‑onset MI 3 (1.8) 5 (5.8) 0.123 4 (2.4) 4 (4.7) 0.448
 Acute HF 4 (2.4) 11 (12.8) 0.001 7 (4.1) 8 (9.3) 0.156
 TVR 12 (7.1) 9 (10.5) 0.346 13 (7.6) 8 (9.3) 0.637
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PCI in non-diabetes patients with STEMI. Measurement 
of in-hospital GV by CGMS in non-diabetes patients 
may improve risk assessment in patients presenting with 
acute STEMI.
Although acute hyperglycemia on admission has 
clearly been associated with poor outcomes in AMI 
patients with or without diabetes, the prognostic value 
of in-hospital GV in this population has been less well 
established. Fluctuations of glucose seem to have more 
deleterious effects than sustained hyperglycemia in the 
development of cardiovascular complications as acute 
glucose excursions activate the oxidative stress [12]. 
More and more evidences show that glycemic variabil-
ity may be an important role in resolving potential car-
diovascular problems in abnormal glucose metabolism. 
Some researchers suggested that glucose excursions is 
independently related to carotid intima-media thickness 
and may contribute to the development of atheroscle-
rosis in individuals with diabetes independent of other 
risk factors [13, 14]. In our previous study, we found 
that GV is an important contributing factor in the sever-
ity of coronary artery disease, which is independent of 
the average level of blood glucose [15]. The Verona Dia-
betes study reported that fasting GV is an independent 
predictor of mortality in type 2 diabetes patients [16]. 
We also found that acute glucose excursions would 
seem to be of greater importance than admission glu-
cose and long-term derangements of glucose metabo-
lism in predicting 1-year outcomes following AMI [17]. 
Some studies concluded that GV was a significant pre-
dictor of mortality in critically ill patients independently 
from mean glucose level and severity of illness [18–20]. 
In the present study, patients with a higher MAGE level 
have higher GRACE risk scores. After 3-month follow-
up, a significantly higher incidence of MACE and car-
diac mortality were found in those patients. Multivariate 
analysis disclosed that in participants, in-hospital GV (i.e. 
MAGE >3.26 mmol/L) was an independent predictor of 
MACE, but ABG was not. The results indicate that high 
glucose fluctuations may be associated with the risk of 
short-term adverse cardiovascular events in non-diabetes 
patients with STEMI after PCI.
Patients with admission hyperglycemia tend to experi-
ence the worst outcomes as demonstrated in several well-
conducted prior studies, our study shows that increased 
glucose excursions should be more important. In this 
study, multivariate analysis shows that in-hospital GV, 
age, LVEF and TIMI flow after PCI were independent 
predictors of short-term MACE, but ABG was not. The 
area under the receiver-operating characteristic curve for 
MAGE and ABG in predicting short-term MACE shows 
that MAGE, but not ABG, displayed significant value in 
predicting short-term MACE in patients. ABG represents 
only a marker of point-in-time glucose status and cannot 
reflect the overall exposure of acute glucose swings. Gly-
cemic disorders are not solely limited to sustained hyper-




























































Fig. 1 a Incidence of MACE after 3‑month follow‑up in relation to 
MAGE levels (white bars MAGE level ≤3.26 mmol/L; black bars MAGE 
level >3.26 mmol/L). b Incidence of MACE after 3‑month follow‑up in 
relation to ABG levels (white bars ABG level ≤7.80 mmol/L; black bars 
ABG level >7.80 mmol/L)
Table 4 Multivariate analysis of  determinants of  short-
term MACE
MACE major adverse cardiac events, HR hazard ratio, CI confidence interval, LVEF 
left ventricular ejection fraction, TIMI thrombolysis in myocardial infarction, PCI 
percutaneous coronary intervention, MAGE the mean amplitude of glycemic 
excursions
Independent variables HR 95% CI p value
Lower Upper
Age (per decade) 2.158 1.435 3.245 <0.001
LVEF <40% 3.137 1.543 6.380 0.002
TIMI flow after PCI < grade 3 2.984 1.276 6.980 0.012
MAGE >3.26 mmol/L 2.271 1.154 4.471 0.018
Page 6 of 8Mi et al. Diabetol Metab Syndr  (2017) 9:20 
which includes both upward and downward acute glu-
cose changes. Patients with similar mean glucose levels 
can have markedly different glycemic variability [21].
Although we did not address the underlying relation-
ship between GV and cardiovascular outcomes following 
PCI in non-diabetes patients with STEMI, both oxidative 
stress and inflammation may be involved in the process. 
GV acutely increases oxidative stress and exaggerates 
inflammation [12, 22]. Some studies reported that the 
apoptosis of endothelial cells exposed to intermittent 
high glucose may be related to a reactive oxygen species 
(ROS) overproduction, through protein kinase C (PKC)-
dependent activation of nicotinamide adenine dinucleo-
tide phosphate-oxidase [23, 24]. In vitro studies indicate 
that glucose fluctuations can activate nuclear factor-κB 
and PKC pathway, leading to a greater expression of the 
adhesion molecules and excess formation of advanced 
glycation end-products than stable high glucose [25, 
26]. These findings suggest that glucose fluctuations 
may augment inflammation via oxidative mechanisms 
closely linked to adverse outcomes. Furthermore, severe 
glycemic excursions may adversely affect sympathetic 
dysfunction which is associated with mortality and mor-
bidity of cardiovascular disease [27]; and the thrombotic 
properties of platelets are increased in a hyperglycemic 
environment, and this can result in additional cardio-
vascular complications [28]. Hypoglycemia is another 
possible link between GV and poorer cardiovascular out-
comes. Some reported that greater GV predicted more 
hypoglycemic episodes. Severe hypoglycemia can pre-
dict all-cause mortality in patients with diabetes [29, 30]. 
Hypoglycemia could induce the onset of MACE through 
induction of inflammation, blood coagulation abnormal-
ity, sympathoadrenal response and endothelial dysfunc-
tion [31].
Moreover, the relationship between GV and cardio-
vascular outcomes is still controversial. There is still an 
extensive debate about GV as a risk factor for MACE 
[32]. The trial, known as HEART2D study, failed to dem-
onstrate that decreasing GV led to reduced MACE risk 
[33]. However, the study was discontinued prematurely 
due to too few MACE and less than expected differences 
in postprandial glucose values. Only one of three mark-
ers of GV was reduced with the prandial-targeted ther-
apy and this was the newest, least established GV marker. 
Different aim of initial study design and measurements of 
GV may be important causes for explaining controver-
sial results in these studies. Overall, more well-designed 
studies are warranted to investigate whether GV will play 
an important role in cardiovascular complications.
Study limitations
Several study limitations should be considered in the 
interpretation of the results. First, diabetes was defined 
as known diabetes status on admission. It is well known 
that a number of STEMI patients have undetected dia-
betes mellitus, and they were not excluded in our study. 
Second, the sample size was relatively small, so that some 
subgroup comparisons may have lacked power to detect 
significant differences for selected variables. Third, hypo-
glycemia is considered as a risk factor of cardiovascular 
events. However, due to very low incidence of hypoglyce-
mic episodes in our study, we didn’t include this risk fac-
tor in analysis. In addition, we examined in-hospital GV 
which couldn’t reflect daily GV at home. Some factors, 
such as different diets, operations, physical and emo-
tional factors, which maybe affect patients’ glucose fluc-
tuations couldn’t be analyzed. On the other hand, some 
limitations of CGMS should be noted including require-
ment for frequent calibrations, invasive techniques, 
complex procedure, and so on. Hence, we think that the 
results of the present study should be interpreted with 
caution. This study is hypothesis-generating and should 
stimulate a larger multicenter evaluation.
Conclusions
In-hospital GV would seem to be of greater importance 
than ABG in predicting short-term cardiovascular out-
comes in non-diabetes patients with STEMI after PCI.
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